Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali

American Journal of Tropical Medicine and Hygiene

Volumn 67, Issue 6, 2002, Pages 604-610

  Coulibaly, Drissa ^a   Diallo, Dapa A ^a   Thera, Mahamadou A ^a   Dicko, Alassane ^a   Guindo, Ando B ^a   Koné, Abdoulaye K ^a   Cissoko, Yacouba ^a   Coulibaly, Seydou ^a   Djimdé, Abdoulaye ^a   Lyke, Kirsten ^b   Doumbo, Ogobara K ^a   Plowe, Christopher V ^b  

^a UNIVERSITY OF BAMAKO   (Mali)

^b University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; FANSIDAR; MALARIA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MALI; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 0036917115     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.67.604     Document Type: Article

References (19)

1. Kwiatkowski D, Marsh K, 1997. Development of a malaria vaccine. Lancet 350: 1696-1701.
2. Clyde DF, 1975. Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. Am J Trop Med Hyg 24: 397-401.
3. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillessen D, Nardin E, Nussenzweig RS, Nussenzweig V, Hollingdale MR, Levine MM, 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328: 257-259.
4. Good MF, Kaslow DC, Miller LH, 1998. Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol 16: 57-87.
5. Heppner DG, Cummings JF, Ockenhouse C, Kester KE, Lyon JA, Gordon DM, 2001. New World monkey efficacy trials for malaria vaccine development: Critical path or detour? Trends Parasitol 17: 419-425.
6. Stowers AW, Miller LH, 2001. Are trials in New World monkeys on the critical path for blood-stage malaria vaccine development? Trends Parasitol 17: 415-419.
7. Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, Strickland GT, Gordon DM, Ballou WR, Bales JDJ, Wirtz RA, Wittes J, Gross M, Que JU, Cryz SJ, Oster CN, Roberts CR, Sadoff JC, 1996. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 14: 817-827.
8. Alonso PL, Smith T, Schellenberg JR, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, Hurt N, Thomas MC, Lyimo E, Weiss NA, Hayes R, Kitua AY, Lopez MC, Kilama WL, Teuscher T, Tanner M, 1994. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344: 1175-1181.
9. D'Alessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GA, Greenwood BM, 1995. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346: 462-467.
10. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM. White NJ, Sadoff JC, Heppner DG, 1996. Randomised double-blind placebocontrolled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet 348: 701-707.
11. Genton B, Betuela I, Felger I, Al Yaman F, Anders RF, Saul A, Rare L, Baisor M, Lorry K, Brown GV, Pye D, Irving DO, Smith TA, Beck HP, Alpers MP, 2002. A recombinant bloodstage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 185: 820-827.
12. Diourte Y, Djimde A, Doumbo OK, Sagara I, Coulibaly Y, Dicko A, Diallo M, Diakite M, Cortese JF, Plowe CV, 1999. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg 60: 475-478.
13. Plowe CV, Doumbo OK, Djimde A, Kayentao K, Diourte Y, Doumbo SN, Coulibaly D, Thera M, Wellems TE, Diallo DA, 2001. Chloroquine treatment of uncomplicated Plasmodium falciparum malaria in Mali: Parasitologic resistance versus therapeutic efficacy. Am J Trop Med Hyg 64: 242-246.
14. Watkins WM, Mosobo M, 1993. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: Selective pressure for resistance is a function of long elimination halflife. Trans R Soc Trop Med Hyg 87: 75-78.
15. Edelman R, Hoffman SL, Davis JR, Beier M, Sztein MB, Losonsky G, Herrington DA, Eddy HA, Hollingdale MR, Gordon DM, Clyde DF, 1993. Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis 168: 1066-1070.
16. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: A randomised trial. Lancet 358: 1927-1934.
17. Otoo LN, Snow RW, Menon A, Byass P, Greenwood BM, 1988. Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis. Trans R Soc Trop Med Hyg 82: 59-65.
18. Otoo LN, Riley EM, Menon A, Byass P, Greenwood BM, 1989. Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis. Trans R Soc Trop Med Hyg 83: 778-782.
19. Greenwood BM, Bradley AK, Greenwood AM, Byass P, Jammeh K, Marsh K, Tulloch S, Oldfield FS, Hayes R, 1987. Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med Hyg 81: 478-486.